The clinical use of biomarkers as prognostic factors in Ewing sarcoma

Table 5 Outcome for biological markers: cell cycle

Author	Year	Biomarker	Pt number	P
Landanyi et al, J Pathol 175 (2), 211-7	1995	MDM-2	30	0.005
Luksch et al, Tumori 85 (2), 101-7[41]	1999	Mitose presence	73	S
Sollazzo et al, tumori 85 (3), 167-73[56]	1999	Ki-67	38	0.01
De Alava et al, Cancer 89, 783-92[25]	2000	Ki-67	55	0.005
Abudu et al, Br J Cancer 79(7-8), 1185-9[57]	1999	P53	50	0.02
Huang et al, J Clin Oncol 23, 548-58[58]	2005	P53	60	0.001
Matsunobu et al, C;in Cancer Res 10, 1003-12[29]	2004	P27	21	0.01
Wei et al, Cancer 89, 793-9[42]	2000	INK4a	39	0.001
Maitra et al, Arch Pathol Lab Med 125, 1207-12[59]	2001	P16INK4a	20	0.41
Maitra et al, Arch Pathol Lab Med 125, 1207-12[59]	2001	P14ARF	20	NS
Huang et al, J Clin Oncol 23, 548-58[58]	2005	P16/p14ARF	60	0.03
Maitra et al, Arch Pathol Lab Med 125, 1207-12[59]	2001	P21WAF1	20	0.61
Ohali et al, Oncogene 23, 8997-9006[60]	2004	Cadherin-11	20	0.024
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32]	2007	STEAP1	28	0.0012
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32]	2007	CCND1	28	0.0077
Martins et al, Cancer Res 68 (15), 6260-70[61]	2008	Heat shock 90	54	S
Zanini et al, Virchows Arch 452, 157-67[62]	2008	Heat shock 27	unknown	NS

ISSN: 2045-3329